Chinese investment into Australian health firms, including supplement manufacturers, will continue to grow as the country's healthcare system matures and the population ages, analysts from KPMG are forecasting.
After successfully completing a Series B financing, Microbiome Therapeutics is gearing up for the launch of a ‘microbiome modulator’ product designed to help balance the microbiome and support healthy metabolism.
Ingredient giant DowDuPont announced that it has completed the Health & Nutrition arm of FMC Corporation—other than its omega-3 business—to build on the former’s “sustainable, bio-based food ingredients” market share.
Pfizer announced that it is “reviewing strategic alternatives” for its Consumer Healthcare business, the parent company of many iconic over-the-counter (OTC) brands from dietary supplements to personal care.
Technological advances are having a big impact on the APAC supplement and functional food industry, with the most innovative firms enjoying "a major boon” as more consumers go online for advice and to make purchases.